Informações:
Falhas:
ID
34357
Descrição
Study To Assess Renewal Of Treatment In Patients Recently Diagnosed With Prostate Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT02238366
Link
https://clinicaltrials.gov/show/NCT02238366
Palavras-chave
Versões (1)
- 16/01/2019 16/01/2019 -
Titular dos direitos
See clinicaltrials.gov
Transferido a
16 de janeiro de 2019
DOI
Para um pedido faça login.
Licença
Creative Commons BY 4.0
Comentários do modelo :
Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.
Comentários do grupo de itens para :
Comentários do item para :
Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.
Eligibility Prostate Cancer NCT02238366
Eligibility Prostate Cancer NCT02238366
- StudyEvent: Eligibility
Similar models
Eligibility Prostate Cancer NCT02238366
- StudyEvent: Eligibility
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de dados
Alias
Adult | Age | Prostate carcinoma Advanced Locally | Metastatic Prostate Carcinoma | Antiandrogen therapy Scheduled | Therapeutic radiology procedure | GnRH Analog | Triptorelin
Item
adult men, ≥18 years old, with recently diagnosed locally advanced or metastatic prostate cancer scheduled to receive androgen deprivation therapy as monotherapy or as concomitant and adjuvant therapy in association with radiation therapy, with a 1 or 3 month gnrh analogue triptorelin formulation
boolean
C0001675 (UMLS CUI [1])
C0001779 (UMLS CUI [2])
C0600139 (UMLS CUI [3,1])
C0205179 (UMLS CUI [3,2])
C1517927 (UMLS CUI [3,3])
C0936223 (UMLS CUI [4])
C0279492 (UMLS CUI [5,1])
C0205539 (UMLS CUI [5,2])
C1522449 (UMLS CUI [6])
C1518041 (UMLS CUI [7])
C0077275 (UMLS CUI [8])
C0001779 (UMLS CUI [2])
C0600139 (UMLS CUI [3,1])
C0205179 (UMLS CUI [3,2])
C1517927 (UMLS CUI [3,3])
C0936223 (UMLS CUI [4])
C0279492 (UMLS CUI [5,1])
C0205539 (UMLS CUI [5,2])
C1522449 (UMLS CUI [6])
C1518041 (UMLS CUI [7])
C0077275 (UMLS CUI [8])
Life Expectancy
Item
expected survival > 12 months.
boolean
C0023671 (UMLS CUI [1])
Informed Consent
Item
patients having provided written informed consent.
boolean
C0021430 (UMLS CUI [1])
Patients Mentally alert | Questionnaire Completion
Item
patients mentally fit for completing a questionnaire.
boolean
C0030705 (UMLS CUI [1,1])
C0424536 (UMLS CUI [1,2])
C0034394 (UMLS CUI [2,1])
C0205197 (UMLS CUI [2,2])
C0424536 (UMLS CUI [1,2])
C0034394 (UMLS CUI [2,1])
C0205197 (UMLS CUI [2,2])
Investigational New Drugs
Item
treatment with any investigational drug within the last 3 months before study entry or planning to participate in a study.
boolean
C0013230 (UMLS CUI [1])
GnRH Analog preceding
Item
patients who already have been treated with a gnrh analogue within the last year.
boolean
C1518041 (UMLS CUI [1,1])
C0332152 (UMLS CUI [1,2])
C0332152 (UMLS CUI [1,2])
Hypersensitivity GnRH | Hypersensitivity GnRH Analog | Triptorelin allergy | Hypersensitivity GnRH Excipient | Hypersensitivity GnRH Analog Excipient | Hypersensitivity Triptorelin Excipient
Item
patients with hypersensitivity to gnrh, gnrh analogue, triptorelin or its excipients.
boolean
C0020517 (UMLS CUI [1,1])
C0023610 (UMLS CUI [1,2])
C0020517 (UMLS CUI [2,1])
C1518041 (UMLS CUI [2,2])
C0571725 (UMLS CUI [3])
C0020517 (UMLS CUI [4,1])
C0023610 (UMLS CUI [4,2])
C0015237 (UMLS CUI [4,3])
C0020517 (UMLS CUI [5,1])
C1518041 (UMLS CUI [5,2])
C0015237 (UMLS CUI [5,3])
C0020517 (UMLS CUI [6,1])
C0077275 (UMLS CUI [6,2])
C0015237 (UMLS CUI [6,3])
C0023610 (UMLS CUI [1,2])
C0020517 (UMLS CUI [2,1])
C1518041 (UMLS CUI [2,2])
C0571725 (UMLS CUI [3])
C0020517 (UMLS CUI [4,1])
C0023610 (UMLS CUI [4,2])
C0015237 (UMLS CUI [4,3])
C0020517 (UMLS CUI [5,1])
C1518041 (UMLS CUI [5,2])
C0015237 (UMLS CUI [5,3])
C0020517 (UMLS CUI [6,1])
C0077275 (UMLS CUI [6,2])
C0015237 (UMLS CUI [6,3])
Medical contraindication
Item
patients with a contraindication according to smpc.
boolean
C1301624 (UMLS CUI [1])